The study conducted in a representative sample of patients with type 2 diabetes, shows that the Pro12Ala polymorphism of PPARγ2 is associated with a significantly lower progression of UAER, a significantly lower decay of GFR, significantly less overall renal damage,- as indicated by the lower incidence of a combined end point of clinically relevant progression of albuminuria and loss of renal function – as compared with carriers of the wild-type Pro/Pro genotype. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.